Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

Merck, a pharmaceutical company headquartered in Rahway, announced it will be undergoing layoffs after a disappointing second ...

The European Commission (EC) has granted conditional approval to SpringWorks Therapeutics’ Ezmekly (mirdametinib) to treat ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

Merck KGaA (NYSE:MRK) said that the European Commission approved Ezmekly for treating symptomatic, inoperable plexiform ...

Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval from the European Commission. The pharmaceutical company said Friday that ...

Merck KGaA: European Commission Grants Conditional Approval for EZMEKLY Published: July 18, 2025 at 12:32 p.m. ET Share Resize ...

STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, ...

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization ...